Otsuka Holdings Co. (OTSKY) 16.6600 $OTSKY
Gastrointestinal Stromal Tumor (GIST) Therapeutics Pipeline Review, H1 2015 - 21 Companies & 28 Drug Profiles
M2 - Thu Jul 09, 9:43AM CDT
Research and Markets (http://www.researchandmarkets.com/research/kdk8kj/gastrointestinal) has announced the addition of the "Gastrointestinal Stromal Tumor (GIST) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Gastrointestinal Stromal Tumor (GIST), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Gastrointestinal Stromal Tumor (GIST) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AB Science - Advenchen Laboratories, LLC - Ariad Pharmaceuticals, Inc. - Array BioPharma Inc. - Astex Pharmaceuticals, Inc. - Blueprint Medicines - Boston Biomedical, Inc. - Chipscreen Biosciences Ltd - Daiichi Sankyo Company, Limited - Deciphera Pharmaceuticals, LLC - F. Hoffmann-La Roche Ltd. - GlaxoSmithKline plc - Jiangsu Hengrui Medicine Co., Ltd. - Natco Pharma Limited - Nerviano Medical Sciences S.r.l. - Novartis AG - Otsuka Holdings Co., Ltd. - Plexxikon Inc. - Synta Pharmaceuticals Corp. - Takeda Pharmaceutical Company Limited - Threshold Pharmaceuticals, Inc. Drug Profiles - (dabrafenib mesylate trametinib dimethyl sulfoxide) - alpelisib - apatinib - BBI-503 - binimetinib - BLU-285 - buparlisib hydrochloride - crenolanib besylate - CS-2164 - DCC-2618 - evofosfamide - ganetespib - LOP-628 - masitinib - motesanib diphosphate - nilotinib - NMSP-088 - NRCAN-019 - onalespib - OPB-51602 - pazopanib hydrochloride - PLX-3397 - ponatinib hydrochloride - quizartinib dihydrochloride - SF-1126 - SHR-1020 - Small Molecules to Inhibit c-Kit for Gastrointestinal Stromal Tumor - vemurafenib For more information visit http://www.researchandmarkets.com/research/kd...intestinal
BPMC: 28.02 (+2.16), GSK: 42.45 (+0.65), SNTA: 2.16 (-0.01), ARRY: 6.84 (+0.09), NVS: 103.22 (+3.20)
Chronic Kidney Disease (Chronic Renal Failure) Pipeline Review, H1 2015 - 28 Companies & 42 Drug Profiles
M2 - Thu Jul 09, 8:27AM CDT
Research and Markets (http://www.researchandmarkets.com/research/58mtw9/chronic_kidney) has announced the addition of the "Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Kidney Disease (Chronic Renal Failure), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Kidney Disease (Chronic Renal Failure) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Acceleron Pharma, Inc. - AFFiRiS AG - Angion Biomedica Corp. - Astellas Pharma Inc. - Bayer AG - Bio-inRen - Boryung Pharmaceutical Co., Ltd. - Celtic Biotech, Ltd. - Concert Pharmaceuticals, Inc. - Eli Lilly and Company - Evotec AG - Intercept Pharmaceuticals, Inc. - La Jolla Pharmaceutical Company - Multi Gene Vascular Systems Ltd - Nippon Zoki Pharmaceutical Co., Ltd. - OPKO Health, Inc. - Otsuka Holdings Co., Ltd. - Prolong Pharmaceuticals - ProMetic Life Sciences Inc. - Quark Pharmaceuticals, Inc. - Reata Pharmaceuticals, Inc. - Red Glead Discovery AB - Resverlogix Corp. - Sphaera Pharma Pvt. Ltd. - Stelic Institute & Co. - Toray Industries, Inc. - VBS Pharmaceuticals - Vicore Pharma AB For more information visit http://www.researchandmarkets.com/research/58...nic_kidney
OPK: 16.55 (-0.01), ICPT: 247.71 (+4.45), LLY: 88.29 (+0.81), CNCE: 15.71 (+0.27), XLRN: 30.03 (+0.20)
Salivary Gland Cancer - Pipeline Review, H1 2015
M2 - Thu Jun 25, 7:42AM CDT
Research and Markets (http://www.researchandmarkets.com/research/r44nq5/salivary_gland) has announced the addition of the "Salivary Gland Cancer - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Salivary Gland Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Salivary Gland Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned - AstraZeneca PLC - Bayer AG - Incuron, LLC - Otsuka Holdings Co., Ltd. - Plexxikon Inc. For more information visit http://www.researchandmarkets.com/research/r4...vary_gland
AZN: 66.45 (+1.90)
Ocular Hypertension - Pipeline Review, H1 2015
M2 - Fri Jun 12, 4:04AM CDT
Research and Markets (http://www.researchandmarkets.com/research/nbvbk4/ocular) has announced the addition of the "Ocular Hypertension - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Ocular Hypertension, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ocular Hypertension and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned - Aerie Pharmaceuticals, Inc. - Allergan, Inc. - Amakem NV - Asahi Kasei Pharma Corp. - Bausch & Lomb Incorporated - Can-Fite BioPharma Ltd. - F. Hoffmann-La Roche Ltd. - Inotek Pharmaceuticals Corporation - Merck & Co., Inc. - Ocular Therapeutix, Inc. - Ono Pharmaceutical Co., Ltd. - Otsuka Holdings Co., Ltd. - Santen Pharmaceutical Co., Ltd. - Sylentis S.A. For more information visit http://www.researchandmarkets.com/research/nbvbk4/ocular
CANF: 2.00 (+0.09), AGN: 312.13 (+8.03), ITEK: 5.11 (+0.25), MRK: 57.95 (+0.57), AERI: 17.80 (+0.12), OCUL: 20.82 (+0.73)
Edema Pipeline Review, H1 2015 - 3 Companies & 6 Drug Profiles
M2 - Tue Jun 09, 6:15AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rtth55/edema_pipeline) has announced the addition of the "Edema - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Edema, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Edema and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Apeptico Forschung und Entwicklung GmbH - Mirrx Therapeutics A/S - Otsuka Holdings Co., Ltd. Drug Profiles - AP-301 - BC-1215 - CD5-2 - Synthetic Peptides for Edema - tolvaptan - X-0002 For more information visit http://www.researchandmarkets.com/research/rt...a_pipeline
Global Tourette Syndrome Pipeline Review, H1 2015 - 9 Companies & 10 Drug Profiles
M2 - Mon Jun 08, 10:14AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vbs28p/tourette_syndrome) has announced the addition of the "Tourette Syndrome - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Tourette Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Tourette Syndrome and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AstraZeneca PLC - Auspex Pharmaceuticals, Inc. - Catalyst Pharmaceutical Partners, Inc. - Edison Pharmaceuticals, Inc. - Neurocrine Biosciences, Inc. - Otsuka Holdings Co., Ltd. - Psyadon Pharmaceuticals, Inc. - Reviva Pharmaceuticals Inc. - Synchroneuron Inc. Drug Profiles - acamprosate calcium SR - aripiprazole - AZD-5213 - CPP-115 - dutetrabenazine ER - ecopipam hydrochloride - RP-5063 - valbenazine - vatiquinone - vigabatrin For more information visit http://www.researchandmarkets.com/research/vb...e_syndrome
NBIX: 48.16 (+0.33), CPRX: 4.88 (+0.20), AZN: 66.45 (+1.90), ASPX: 100.96 (unch)
Global Anxiety Disorders Pipeline Review, H1 2015
M2 - Mon Jun 08, 9:36AM CDT
Research and Markets (http://www.researchandmarkets.com/research/v6j3ln/anxiety_disorders) has announced the addition of the "Anxiety Disorders - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Anxiety Disorders, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Anxiety Disorders and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AbbVie Inc. - Ache Laboratorios Farmaceuticos S/A - Adamed Sp. z o.o. - Addex Therapeutics Ltd - Avineuro Pharmaceuticals, Inc. - Azevan Pharmaceuticals, Inc. - Beech Tree Labs, Inc. - Bionomics Limited - Boehringer Ingelheim GmbH - C4X Discovery Ltd - Catalyst Pharmaceutical Partners, Inc. - Concert Pharmaceuticals, Inc. - Edgemont Pharmaceuticals, LLC - Eisai Co., Ltd. - Eli Lilly and Company - F. Hoffmann-La Roche Ltd. - GW Pharmaceuticals plc - H. Lundbeck A/S - Heptares Therapeutics Ltd. - HolsboerMaschmeyer NeuroChemie GmbH - Humanetics Corporation - Intra-Cellular Therapies, Inc. - Johnson & Johnson - Marinus Pharmaceuticals, Inc. - Merz Pharmaceuticals GmbH - MI.TO. Technology S.r.L. - Nanotherapeutics, Inc. - Neuralstem, Inc. - Neurocrine Biosciences, Inc. - NeuroNascent, Inc. - Newron Pharmaceuticals S.p.A. - Novartis AG - Nuvo Research Inc. - Omeros Corporation - Otsuka Holdings Co., Ltd. - Pfizer Inc. For more information visit http://www.researchandmarkets.com/research/v6..._disorders
PFE: 34.36 (+0.50), LLY: 88.29 (+0.81), CNCE: 15.71 (+0.27), OMER: 17.33 (+0.29), JNJ: 99.53 (+1.13), NBIX: 48.16 (+0.33), CPRX: 4.88 (+0.20), MRNS: 13.62 (+1.72), ABBV: 69.23 (+1.26), ITCI: 34.76 (+1.70), CUR: 1.69 (-0.01), NVS: 103.22 (+3.20)
Global Treatment Resistant Depression Therapeutics Pipeline Report 2015 - 7 Companies & 12 Drug Profiles
M2 - Fri Jun 05, 8:11AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bhpbqw/treatment) has announced the addition of the "Treatment Resistant Depression - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Treatment Resistant Depression, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Treatment Resistant Depression and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Addex Therapeutics Ltd - Amorsa Therapeutics Inc. - Edgemont Pharmaceuticals, LLC - F. Hoffmann-La Roche Ltd. - Johnson & Johnson - MarcoPolo Pharmaceuticals SA - Otsuka Holdings Co., Ltd. Drug Profiles - (dextromethorphan hydrobromide quinidine sulfate) - AVP-786 - basimglurant - BC-19 - EDG-006 - esketamine hydrochloride - EVT-100 Series - EVT-103 - KA-ER12 - KA-FA - Small Molecule to Modulate Glutamate Receptor for Anxiety Disorders - Small Molecules to Inhibit mGluR2 for Central Nervous System Disorders For more information visit http://www.researchandmarkets.com/research/bhpbqw/treatment
JNJ: 99.53 (+1.13)
Dyskinesia - Pipeline Review, H1 2015
M2 - Wed Jun 03, 9:36AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2wzs3f/dyskinesia) has announced the addition of the "Dyskinesia - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Dyskinesia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Dyskinesia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned - Adamas Pharmaceuticals, Inc. - Addex Therapeutics Ltd - Advicenne Pharma - Amarantus Bioscience Holdings, Inc. - Astraea Therapeutics, LLC - Auspex Pharmaceuticals, Inc. - BioMarin Pharmaceutical Inc. - Catalyst Pharmaceutical Partners, Inc. - Contera Pharma ApS - EpiVax, Inc. - Heptares Therapeutics Ltd. - Integrative Research Laboratories Sweden AB - Ipsen S.A. - Medicure Inc. - Medy-Tox Inc. - Merz Pharmaceuticals GmbH - Neurim Pharmaceuticals Ltd - Neurocrine Biosciences, Inc. - Neurolixis Inc. - Novartis AG - Osmotica Pharmaceutical Corp. - Otsuka Holdings Co., Ltd. - Santhera Pharmaceuticals Holding AG - SciFluor Life Sciences, LLC - Synchroneuron Inc. - Targacept, Inc. - Upsher-Smith Laboratories, Inc. For more information visit http://www.researchandmarkets.com/research/2wzs3f/dyskinesia
NBIX: 48.16 (+0.33), BMRN: 141.67 (+1.54), TRGT: 2.68 (-0.06), CPRX: 4.88 (+0.20), ASPX: 100.96 (unch), NVS: 103.22 (+3.20)
European Commission clears Otsuka Pharma's Jinarc for kidney disease
Seeking Alpha - at Seeking Alpha - Wed May 27, 9:25AM CDT
Keratoconjunctivitis sicca (Dry Eye) - Pipeline Review, H1 2015
M2 - Wed May 27, 9:13AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3vmksm/keratoconjunctivit) has announced the addition of the "Keratoconjunctivitis sicca (Dry Eye) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Keratoconjunctivitis sicca (Dry Eye), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Keratoconjunctivitis sicca (Dry Eye) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Allergan, Inc. - Celsus Therapeutics Plc - Circadian Technologies Limited - Digna Biotech, S.L. - Dompe Farmaceutici S.p.A. - Dong-A Socio Group - Eleven Biotherapeutics Inc. - EyeGate Pharmaceuticals, Inc. - HanAll Biopharma Co., Ltd. - Herantis Pharma plc. - Huons Co., Ltd. - InSite Vision Incorporated - Kainos Medicine, Inc. - Kala Pharmaceuticals, Inc. - Kissei Pharmaceutical Co., Ltd. - Laboratorios Sophia S.A. de C.V. - Lipicard Technologies Limited - LTT Bio-Pharma Co., Ltd. - Merck & Co., Inc. - Mimetogen Pharmaceuticals Inc. - Neuroptis Biotech - NovaBay Pharmaceuticals, Inc. - Novaliq GmbH - Ocular Therapeutix, Inc. - OncoNOx ApS - Otsuka Holdings Co., Ltd. - Parion Sciences, Inc. - R-Tech Ueno, Ltd. - RegeneRx Biopharmaceuticals, Inc. - Resolvyx Pharmaceuticals, Inc - Santen Pharmaceutical Co., Ltd. - Scynexis, Inc. - Seikagaku Corporation - Shire Plc - SIFI S.p.A For more information visit http://www.researchandmarkets.com/research/3v...njunctivit
OCUL: 20.82 (+0.73), AGN: 312.13 (+8.03), SHPG: 250.34 (+7.35), MRK: 57.95 (+0.57), CLTX: 0.49 (-0.02)
Global Salivary Gland Cancer Clinical Trials Review 2015
M2 - Wed May 27, 8:29AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4l5f2b/salivary_gland) has announced the addition of the "Salivary Gland Cancer Global Clinical Trials Review, H1, 2015" report to their offering. Salivary Gland Cancer Global Clinical Trials Review, H1, 2015" provides data on the Salivary Gland Cancer clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Salivary Gland Cancer. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Salivary Gland Cancer. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Clinical Trial Overview of Top Companies - AstraZeneca PLC - Bristol-Myers Squibb Company - Otsuka Holdings Co., Ltd. - Biotec Pharmacon ASA Clinical Trial Overview of Top Institutes / Government - National Cancer Institute - Fox Chase Cancer Center - University Health Network - University of Washington - Eastern Cooperative Oncology Group - University of Chicago - University of Texas M. D. Anderson Cancer Center - Ontario Clinical Oncology Group - Stanford University For more information visit http://www.researchandmarkets.com/research/4l...vary_gland
AZN: 66.45 (+1.90), BMY: 69.27 (+1.38)
Otsuka Enters Urology Field with Non-Invasive and Continuous Urine Volume Sensor Technology
Business Wire - Mon May 04, 1:53AM CDT
Lilium Otsuka Co., Ltd., an affiliated company of Otsuka Holdings Co., Ltd., (TOKYO:4578) announced that the National Institute of Advanced Industrial Science and Technology (AIST), UriCare Inc., and Lilium Otsuka signed a contract for research and development and marketing of products using ultrasound urinary volume sensor technology owned by UriCare and AIST.
FDA clears generic versions of Otsuka's Abilify antidepressant
Seeking Alpha - at Seeking Alpha - Tue Apr 28, 2:49PM CDT
TEVA: 61.38 (-0.75)
Dermatitis Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com
PRWeb - Tue Apr 21, 10:31AM CDT
The report "Dermatitis - Pipeline Review, H1 2015" provides comparative analysis on the therapeutic development for Dermatitis. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report with TOC is available @ http://www.rnrmarketresearch.com/dermatitis-p...eport.html .
VTAE: 10.26 (-0.25), FOMX: 11.18 (+0.22), PVCT: 0.51 (+0.01), JNJ: 99.53 (+1.13), DERM: 18.22 (+0.30), ANAC: 84.61 (+1.95), XNCR: 22.60 (+0.13), REGN: 526.01 (+16.98), AQXP: 1.94 (-0.19), BMY: 69.27 (+1.38), GSK: 42.45 (+0.65), VRX.TO: 294.65 (+11.22), CBPO: 111.03 (+7.77), MRK: 57.95 (+0.57), CCXI: 8.60 (+0.19), CLTX: 0.49 (-0.02), CELGZ: 2.15 (+0.14), NVS: 103.22 (+3.20)
How To Play Japanese Monopoly
Matthew Waterman - at Seeking Alpha - Tue Apr 21, 5:08AM CDT
SNE: 28.40 (+1.04), TM: 131.52 (+2.49), DCM: 19.16 (+0.26), MFG: 4.27 (+0.13), MAT: 25.38 (-0.40), SMFG: 8.71 (+0.23), S: 3.78 (-0.12), HMC: 31.68 (+0.38), MSFT: 44.61 (+0.09), KNM: 19.29 (+0.36), MTU: 7.11 (+0.25)
Phase 3 study shows efficacy of brexpiprazole in schizophrenia
Seeking Alpha - at Seeking Alpha - Fri Apr 17, 9:32AM CDT
Tourette Syndrome Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com
PRWeb - Tue Apr 14, 11:02AM CDT
The report "Tourette Syndrome - Pipeline Review, H1 2015" provides comparative analysis on the therapeutic development for Tourette Syndrome. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report with TOC is available @ http://www.rnrmarketresearch.com/tourette-syn...eport.html .
NBIX: 48.16 (+0.33), CPRX: 4.88 (+0.20), ASPX: 100.96 (unch)
ReCor Medical Announces New Lead Investor and Upcoming Hypertension Trial
PR Newswire Europe - Fri Apr 10, 12:54PM CDT
ReCor Medical, Inc., a Palo Alto- and Amsterdam-based medical device firm, announced today a Series D investment of approximately $15M led by Otsuka Holdings Co., Ltd., the parent company of Otsuka Pharmaceutical and the Otsuka group of healthcare companies. Otsuka Holdings, one of the leading healthcare groups in Japan, joined Sofinnova Partners in the Series D round. In addition, ReCor has met with the US FDA regarding a new randomized controlled trial of its Paradise Renal Denervation ("RDN"
System in hypertensive patients to demonstrate its effect on blood pressure in conjunction with, and in the absence of, hypertensive drug therapy. The Company is planning to conduct the new study at 20 - 25 sites in the US and EU.
BSX: 17.60 (+0.15)
Gastrointestinal Stromal Tumor (GIST) Therapeutics Pipeline Review, H1 2015 - 21 Companies & 28 Drug Profiles
M2 - Thu Jul 09, 9:43AM CDT
Research and Markets (http://www.researchandmarkets.com/research/kdk8kj/gastrointestinal) has announced the addition of the "Gastrointestinal Stromal Tumor (GIST) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Gastrointestinal Stromal Tumor (GIST), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Gastrointestinal Stromal Tumor (GIST) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AB Science - Advenchen Laboratories, LLC - Ariad Pharmaceuticals, Inc. - Array BioPharma Inc. - Astex Pharmaceuticals, Inc. - Blueprint Medicines - Boston Biomedical, Inc. - Chipscreen Biosciences Ltd - Daiichi Sankyo Company, Limited - Deciphera Pharmaceuticals, LLC - F. Hoffmann-La Roche Ltd. - GlaxoSmithKline plc - Jiangsu Hengrui Medicine Co., Ltd. - Natco Pharma Limited - Nerviano Medical Sciences S.r.l. - Novartis AG - Otsuka Holdings Co., Ltd. - Plexxikon Inc. - Synta Pharmaceuticals Corp. - Takeda Pharmaceutical Company Limited - Threshold Pharmaceuticals, Inc. Drug Profiles - (dabrafenib mesylate trametinib dimethyl sulfoxide) - alpelisib - apatinib - BBI-503 - binimetinib - BLU-285 - buparlisib hydrochloride - crenolanib besylate - CS-2164 - DCC-2618 - evofosfamide - ganetespib - LOP-628 - masitinib - motesanib diphosphate - nilotinib - NMSP-088 - NRCAN-019 - onalespib - OPB-51602 - pazopanib hydrochloride - PLX-3397 - ponatinib hydrochloride - quizartinib dihydrochloride - SF-1126 - SHR-1020 - Small Molecules to Inhibit c-Kit for Gastrointestinal Stromal Tumor - vemurafenib For more information visit http://www.researchandmarkets.com/research/kd...intestinal
BPMC: 28.02 (+2.16), GSK: 42.45 (+0.65), SNTA: 2.16 (-0.01), ARRY: 6.84 (+0.09), NVS: 103.22 (+3.20)
Chronic Kidney Disease (Chronic Renal Failure) Pipeline Review, H1 2015 - 28 Companies & 42 Drug Profiles
M2 - Thu Jul 09, 8:27AM CDT
Research and Markets (http://www.researchandmarkets.com/research/58mtw9/chronic_kidney) has announced the addition of the "Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Kidney Disease (Chronic Renal Failure), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Kidney Disease (Chronic Renal Failure) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Acceleron Pharma, Inc. - AFFiRiS AG - Angion Biomedica Corp. - Astellas Pharma Inc. - Bayer AG - Bio-inRen - Boryung Pharmaceutical Co., Ltd. - Celtic Biotech, Ltd. - Concert Pharmaceuticals, Inc. - Eli Lilly and Company - Evotec AG - Intercept Pharmaceuticals, Inc. - La Jolla Pharmaceutical Company - Multi Gene Vascular Systems Ltd - Nippon Zoki Pharmaceutical Co., Ltd. - OPKO Health, Inc. - Otsuka Holdings Co., Ltd. - Prolong Pharmaceuticals - ProMetic Life Sciences Inc. - Quark Pharmaceuticals, Inc. - Reata Pharmaceuticals, Inc. - Red Glead Discovery AB - Resverlogix Corp. - Sphaera Pharma Pvt. Ltd. - Stelic Institute & Co. - Toray Industries, Inc. - VBS Pharmaceuticals - Vicore Pharma AB For more information visit http://www.researchandmarkets.com/research/58...nic_kidney
OPK: 16.55 (-0.01), ICPT: 247.71 (+4.45), LLY: 88.29 (+0.81), CNCE: 15.71 (+0.27), XLRN: 30.03 (+0.20)
Salivary Gland Cancer - Pipeline Review, H1 2015
M2 - Thu Jun 25, 7:42AM CDT
Research and Markets (http://www.researchandmarkets.com/research/r44nq5/salivary_gland) has announced the addition of the "Salivary Gland Cancer - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Salivary Gland Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Salivary Gland Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned - AstraZeneca PLC - Bayer AG - Incuron, LLC - Otsuka Holdings Co., Ltd. - Plexxikon Inc. For more information visit http://www.researchandmarkets.com/research/r4...vary_gland
AZN: 66.45 (+1.90)
Ocular Hypertension - Pipeline Review, H1 2015
M2 - Fri Jun 12, 4:04AM CDT
Research and Markets (http://www.researchandmarkets.com/research/nbvbk4/ocular) has announced the addition of the "Ocular Hypertension - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Ocular Hypertension, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ocular Hypertension and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned - Aerie Pharmaceuticals, Inc. - Allergan, Inc. - Amakem NV - Asahi Kasei Pharma Corp. - Bausch & Lomb Incorporated - Can-Fite BioPharma Ltd. - F. Hoffmann-La Roche Ltd. - Inotek Pharmaceuticals Corporation - Merck & Co., Inc. - Ocular Therapeutix, Inc. - Ono Pharmaceutical Co., Ltd. - Otsuka Holdings Co., Ltd. - Santen Pharmaceutical Co., Ltd. - Sylentis S.A. For more information visit http://www.researchandmarkets.com/research/nbvbk4/ocular
CANF: 2.00 (+0.09), AGN: 312.13 (+8.03), ITEK: 5.11 (+0.25), MRK: 57.95 (+0.57), AERI: 17.80 (+0.12), OCUL: 20.82 (+0.73)
Edema Pipeline Review, H1 2015 - 3 Companies & 6 Drug Profiles
M2 - Tue Jun 09, 6:15AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rtth55/edema_pipeline) has announced the addition of the "Edema - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Edema, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Edema and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Apeptico Forschung und Entwicklung GmbH - Mirrx Therapeutics A/S - Otsuka Holdings Co., Ltd. Drug Profiles - AP-301 - BC-1215 - CD5-2 - Synthetic Peptides for Edema - tolvaptan - X-0002 For more information visit http://www.researchandmarkets.com/research/rt...a_pipeline
Global Tourette Syndrome Pipeline Review, H1 2015 - 9 Companies & 10 Drug Profiles
M2 - Mon Jun 08, 10:14AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vbs28p/tourette_syndrome) has announced the addition of the "Tourette Syndrome - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Tourette Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Tourette Syndrome and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AstraZeneca PLC - Auspex Pharmaceuticals, Inc. - Catalyst Pharmaceutical Partners, Inc. - Edison Pharmaceuticals, Inc. - Neurocrine Biosciences, Inc. - Otsuka Holdings Co., Ltd. - Psyadon Pharmaceuticals, Inc. - Reviva Pharmaceuticals Inc. - Synchroneuron Inc. Drug Profiles - acamprosate calcium SR - aripiprazole - AZD-5213 - CPP-115 - dutetrabenazine ER - ecopipam hydrochloride - RP-5063 - valbenazine - vatiquinone - vigabatrin For more information visit http://www.researchandmarkets.com/research/vb...e_syndrome
NBIX: 48.16 (+0.33), CPRX: 4.88 (+0.20), AZN: 66.45 (+1.90), ASPX: 100.96 (unch)
Global Anxiety Disorders Pipeline Review, H1 2015
M2 - Mon Jun 08, 9:36AM CDT
Research and Markets (http://www.researchandmarkets.com/research/v6j3ln/anxiety_disorders) has announced the addition of the "Anxiety Disorders - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Anxiety Disorders, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Anxiety Disorders and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AbbVie Inc. - Ache Laboratorios Farmaceuticos S/A - Adamed Sp. z o.o. - Addex Therapeutics Ltd - Avineuro Pharmaceuticals, Inc. - Azevan Pharmaceuticals, Inc. - Beech Tree Labs, Inc. - Bionomics Limited - Boehringer Ingelheim GmbH - C4X Discovery Ltd - Catalyst Pharmaceutical Partners, Inc. - Concert Pharmaceuticals, Inc. - Edgemont Pharmaceuticals, LLC - Eisai Co., Ltd. - Eli Lilly and Company - F. Hoffmann-La Roche Ltd. - GW Pharmaceuticals plc - H. Lundbeck A/S - Heptares Therapeutics Ltd. - HolsboerMaschmeyer NeuroChemie GmbH - Humanetics Corporation - Intra-Cellular Therapies, Inc. - Johnson & Johnson - Marinus Pharmaceuticals, Inc. - Merz Pharmaceuticals GmbH - MI.TO. Technology S.r.L. - Nanotherapeutics, Inc. - Neuralstem, Inc. - Neurocrine Biosciences, Inc. - NeuroNascent, Inc. - Newron Pharmaceuticals S.p.A. - Novartis AG - Nuvo Research Inc. - Omeros Corporation - Otsuka Holdings Co., Ltd. - Pfizer Inc. For more information visit http://www.researchandmarkets.com/research/v6..._disorders
PFE: 34.36 (+0.50), LLY: 88.29 (+0.81), CNCE: 15.71 (+0.27), OMER: 17.33 (+0.29), JNJ: 99.53 (+1.13), NBIX: 48.16 (+0.33), CPRX: 4.88 (+0.20), MRNS: 13.62 (+1.72), ABBV: 69.23 (+1.26), ITCI: 34.76 (+1.70), CUR: 1.69 (-0.01), NVS: 103.22 (+3.20)
Global Treatment Resistant Depression Therapeutics Pipeline Report 2015 - 7 Companies & 12 Drug Profiles
M2 - Fri Jun 05, 8:11AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bhpbqw/treatment) has announced the addition of the "Treatment Resistant Depression - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Treatment Resistant Depression, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Treatment Resistant Depression and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Addex Therapeutics Ltd - Amorsa Therapeutics Inc. - Edgemont Pharmaceuticals, LLC - F. Hoffmann-La Roche Ltd. - Johnson & Johnson - MarcoPolo Pharmaceuticals SA - Otsuka Holdings Co., Ltd. Drug Profiles - (dextromethorphan hydrobromide quinidine sulfate) - AVP-786 - basimglurant - BC-19 - EDG-006 - esketamine hydrochloride - EVT-100 Series - EVT-103 - KA-ER12 - KA-FA - Small Molecule to Modulate Glutamate Receptor for Anxiety Disorders - Small Molecules to Inhibit mGluR2 for Central Nervous System Disorders For more information visit http://www.researchandmarkets.com/research/bhpbqw/treatment
JNJ: 99.53 (+1.13)
Dyskinesia - Pipeline Review, H1 2015
M2 - Wed Jun 03, 9:36AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2wzs3f/dyskinesia) has announced the addition of the "Dyskinesia - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Dyskinesia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Dyskinesia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned - Adamas Pharmaceuticals, Inc. - Addex Therapeutics Ltd - Advicenne Pharma - Amarantus Bioscience Holdings, Inc. - Astraea Therapeutics, LLC - Auspex Pharmaceuticals, Inc. - BioMarin Pharmaceutical Inc. - Catalyst Pharmaceutical Partners, Inc. - Contera Pharma ApS - EpiVax, Inc. - Heptares Therapeutics Ltd. - Integrative Research Laboratories Sweden AB - Ipsen S.A. - Medicure Inc. - Medy-Tox Inc. - Merz Pharmaceuticals GmbH - Neurim Pharmaceuticals Ltd - Neurocrine Biosciences, Inc. - Neurolixis Inc. - Novartis AG - Osmotica Pharmaceutical Corp. - Otsuka Holdings Co., Ltd. - Santhera Pharmaceuticals Holding AG - SciFluor Life Sciences, LLC - Synchroneuron Inc. - Targacept, Inc. - Upsher-Smith Laboratories, Inc. For more information visit http://www.researchandmarkets.com/research/2wzs3f/dyskinesia
NBIX: 48.16 (+0.33), BMRN: 141.67 (+1.54), TRGT: 2.68 (-0.06), CPRX: 4.88 (+0.20), ASPX: 100.96 (unch), NVS: 103.22 (+3.20)
European Commission clears Otsuka Pharma's Jinarc for kidney disease
Seeking Alpha - at Seeking Alpha - Wed May 27, 9:25AM CDT
Keratoconjunctivitis sicca (Dry Eye) - Pipeline Review, H1 2015
M2 - Wed May 27, 9:13AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3vmksm/keratoconjunctivit) has announced the addition of the "Keratoconjunctivitis sicca (Dry Eye) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Keratoconjunctivitis sicca (Dry Eye), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Keratoconjunctivitis sicca (Dry Eye) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Allergan, Inc. - Celsus Therapeutics Plc - Circadian Technologies Limited - Digna Biotech, S.L. - Dompe Farmaceutici S.p.A. - Dong-A Socio Group - Eleven Biotherapeutics Inc. - EyeGate Pharmaceuticals, Inc. - HanAll Biopharma Co., Ltd. - Herantis Pharma plc. - Huons Co., Ltd. - InSite Vision Incorporated - Kainos Medicine, Inc. - Kala Pharmaceuticals, Inc. - Kissei Pharmaceutical Co., Ltd. - Laboratorios Sophia S.A. de C.V. - Lipicard Technologies Limited - LTT Bio-Pharma Co., Ltd. - Merck & Co., Inc. - Mimetogen Pharmaceuticals Inc. - Neuroptis Biotech - NovaBay Pharmaceuticals, Inc. - Novaliq GmbH - Ocular Therapeutix, Inc. - OncoNOx ApS - Otsuka Holdings Co., Ltd. - Parion Sciences, Inc. - R-Tech Ueno, Ltd. - RegeneRx Biopharmaceuticals, Inc. - Resolvyx Pharmaceuticals, Inc - Santen Pharmaceutical Co., Ltd. - Scynexis, Inc. - Seikagaku Corporation - Shire Plc - SIFI S.p.A For more information visit http://www.researchandmarkets.com/research/3v...njunctivit
OCUL: 20.82 (+0.73), AGN: 312.13 (+8.03), SHPG: 250.34 (+7.35), MRK: 57.95 (+0.57), CLTX: 0.49 (-0.02)
Global Salivary Gland Cancer Clinical Trials Review 2015
M2 - Wed May 27, 8:29AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4l5f2b/salivary_gland) has announced the addition of the "Salivary Gland Cancer Global Clinical Trials Review, H1, 2015" report to their offering. Salivary Gland Cancer Global Clinical Trials Review, H1, 2015" provides data on the Salivary Gland Cancer clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Salivary Gland Cancer. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Salivary Gland Cancer. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Clinical Trial Overview of Top Companies - AstraZeneca PLC - Bristol-Myers Squibb Company - Otsuka Holdings Co., Ltd. - Biotec Pharmacon ASA Clinical Trial Overview of Top Institutes / Government - National Cancer Institute - Fox Chase Cancer Center - University Health Network - University of Washington - Eastern Cooperative Oncology Group - University of Chicago - University of Texas M. D. Anderson Cancer Center - Ontario Clinical Oncology Group - Stanford University For more information visit http://www.researchandmarkets.com/research/4l...vary_gland
AZN: 66.45 (+1.90), BMY: 69.27 (+1.38)
Otsuka Enters Urology Field with Non-Invasive and Continuous Urine Volume Sensor Technology
Business Wire - Mon May 04, 1:53AM CDT
Lilium Otsuka Co., Ltd., an affiliated company of Otsuka Holdings Co., Ltd., (TOKYO:4578) announced that the National Institute of Advanced Industrial Science and Technology (AIST), UriCare Inc., and Lilium Otsuka signed a contract for research and development and marketing of products using ultrasound urinary volume sensor technology owned by UriCare and AIST.
FDA clears generic versions of Otsuka's Abilify antidepressant
Seeking Alpha - at Seeking Alpha - Tue Apr 28, 2:49PM CDT
TEVA: 61.38 (-0.75)
Dermatitis Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com
PRWeb - Tue Apr 21, 10:31AM CDT
The report "Dermatitis - Pipeline Review, H1 2015" provides comparative analysis on the therapeutic development for Dermatitis. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report with TOC is available @ http://www.rnrmarketresearch.com/dermatitis-p...eport.html .
VTAE: 10.26 (-0.25), FOMX: 11.18 (+0.22), PVCT: 0.51 (+0.01), JNJ: 99.53 (+1.13), DERM: 18.22 (+0.30), ANAC: 84.61 (+1.95), XNCR: 22.60 (+0.13), REGN: 526.01 (+16.98), AQXP: 1.94 (-0.19), BMY: 69.27 (+1.38), GSK: 42.45 (+0.65), VRX.TO: 294.65 (+11.22), CBPO: 111.03 (+7.77), MRK: 57.95 (+0.57), CCXI: 8.60 (+0.19), CLTX: 0.49 (-0.02), CELGZ: 2.15 (+0.14), NVS: 103.22 (+3.20)
How To Play Japanese Monopoly
Matthew Waterman - at Seeking Alpha - Tue Apr 21, 5:08AM CDT
SNE: 28.40 (+1.04), TM: 131.52 (+2.49), DCM: 19.16 (+0.26), MFG: 4.27 (+0.13), MAT: 25.38 (-0.40), SMFG: 8.71 (+0.23), S: 3.78 (-0.12), HMC: 31.68 (+0.38), MSFT: 44.61 (+0.09), KNM: 19.29 (+0.36), MTU: 7.11 (+0.25)
Phase 3 study shows efficacy of brexpiprazole in schizophrenia
Seeking Alpha - at Seeking Alpha - Fri Apr 17, 9:32AM CDT
Tourette Syndrome Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com
PRWeb - Tue Apr 14, 11:02AM CDT
The report "Tourette Syndrome - Pipeline Review, H1 2015" provides comparative analysis on the therapeutic development for Tourette Syndrome. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report with TOC is available @ http://www.rnrmarketresearch.com/tourette-syn...eport.html .
NBIX: 48.16 (+0.33), CPRX: 4.88 (+0.20), ASPX: 100.96 (unch)
ReCor Medical Announces New Lead Investor and Upcoming Hypertension Trial
PR Newswire Europe - Fri Apr 10, 12:54PM CDT
ReCor Medical, Inc., a Palo Alto- and Amsterdam-based medical device firm, announced today a Series D investment of approximately $15M led by Otsuka Holdings Co., Ltd., the parent company of Otsuka Pharmaceutical and the Otsuka group of healthcare companies. Otsuka Holdings, one of the leading healthcare groups in Japan, joined Sofinnova Partners in the Series D round. In addition, ReCor has met with the US FDA regarding a new randomized controlled trial of its Paradise Renal Denervation ("RDN"
System in hypertensive patients to demonstrate its effect on blood pressure in conjunction with, and in the absence of, hypertensive drug therapy. The Company is planning to conduct the new study at 20 - 25 sites in the US and EU. BSX: 17.60 (+0.15)
